Fig. 2

Efficacy and specificity of anti-CD99 CAR T cells in CDXs and PDXs of T-ALL. a Schematic outline of the mouse model experiment. NCG mice (n=5/6 per group) were i.v. injected with GFP and luciferase labeled Jurkat, MOLT-4 and two patients’ blast cells (Patient #1 and Patient #2), then, administered 5×106 anti-CD99 CAR T cells or 5×106 T cells per mouse at day 3 following leukemia cells injection. Tumor burden was monitored weekly by IVIS imaging or FACS analysis. All the Methods and Materials were described in the Additional file 6. b Tumor progression was monitored using bioluminescent imaging. Scales are normalized for each time points. c The proportion of human CD7 positive cells (leukemia cells) in PB of nonETP ALL PDX (derived from patient #1) model from day 0 to day 43. d-g Kaplan-Meier survival curves of Jurkat CDX mice d, MOLT-4 CDX mice e, nonETP ALL PDX mice f and ETP ALL PDX mice g treated with T cells or anti-CD99 CAR T cells. h The proportion of GFP positive leukemia cells in the spleen in the T cell or anti-CD99 CAR T cell treatment groups according to FACS analysis. Upper: Jurkat CDX model; Lower: MOLT-4 CDX model. i The proportion of human CD7 positive cells in the BM of PDX models. Upper: PDX-1 model; Lower: PDX-2 model. j Anti-CD99 CAR T cell expansion and persistence in Jurkat CDX mice. Assessment of the copy numbers of CARs in whole blood cells by q-PCR on different days. k The Jurkat CDX mice body weight in different treatment groups. IgG as the negative control. ***p ≤ 0.001, **p ≤ 0.01, NS no significant